You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.
News

RenovoDerm Hires Michael Morello as Vice President of Sales & Marketing

Mike-Morello-VP-Sales-Marketing-Renovoderm

RenovoDerm, a wound care device company, announced today that Michael Morello has joined the company’s senior leadership team as Vice President of Sales & Marketing.

A new position for the company, Morello will be responsible for developing and implementing strategies to take RenovoDerm products, including the recently FDA cleared Phoenix Wound MatrixTM, to federal and commercial markets. In addition to delivering on the overall marketing and sales strategy, he will also be responsible for day-to-day marketing activities, such as messaging, customer pricing, reimbursement strategy, contracting third-party vendors, and expense management.

"Michael has a proven history of commercializing high-performing sales teams, and he has a leadership style that fosters a culture of high-engagement and execution excellence," said Ross Kayuha, CEO of RenovoDerm. "After our Phoenix Wound MatrixTM received FDA clearance, we knew that we needed someone with exceptional industry experience to join the team and ensure that the product could succeed in our target markets. We are confident that Michael is the right person to help RenovoDerm become a major player in the wound care space."

Morello has more than 20 years of industry experience, including 12 years in formal business leadership roles with Amylin Pharmaceuticals, Shire Regenerative Medicine and Osiris Therapeutics, where he served as Federal National Sales Director. His most recent endeavor was launching and running his own medical distribution company in 2016, where he delivered wound care products and technologies to federal government and private commercial accounts nationally.

"I am excited to make an impact on the future of RenovoDerm as a business," said Morello. "After starting my own distributorship, I always said that going back to corporate would require a unique opportunity, and this role checks all those boxes. The long-term opportunities here are a no-brainer to me, and I’m truly looking forward to identifying new market opportunities and helping grow the business."

RenovoDerm is a subsidiary company of ParaGen Technologies. ParaGen, a joint venture between Nanofiber Solutions, which aids in developing the core technology, and Ikove Venture Partners, which provides full operational support, market strategy, and access to funding via a global network of investors.

News

RenovoDerm receives FDA clearance for Phoenix Wound Matrix

Today, RenovoDerm announced that the U.S. Food and Drug Administration (FDA) has cleared its proprietary product, the Phoenix Wound Matrix.

The Phoenix Wound Matrix is a fully resorbable electrospun device designed to mimic the extracellular matrix (ECM) found naturally in the body. This product will be used for the treatment of acute, chronic, and burn wounds, which continues to be a concern for both doctors and patients.



Learn More
RenovoDerm-Phoenix-Wound-Matrix-FDA-Clearance